Arecor Therapeutics plc on LinkedIn: Arecor’s fast-acting insulin shows superior results in diabetes trial (2024)

Join us at 2:30pm BST today when Sarah Howell, our CEO and Thomas Pieber, Principal Investigator for the AT278 Phase I clinical trial, will be hosting a CEO and KOL webinar to discuss the positive headline clinical results for our ultra-concentrated, ultra-rapid acting insulin candidate, AT278.Register to join the live webcast here: https://lnkd.in/eczwHZet#Arecor #insulin #diabetes #biotech #insulinpumps

31

We are pleased to announce positive headline results for AT278, our ultra-concentrated and ultra-rapid acting insulin which has demonstrated superiority in a Phase I clinical trial people with Type 2 diabetes who are overweight and obese.✔ AT278, met all primary and secondary endpoints, and also demonstrated superiority to current treatment options NovoRapid® and Humulin® R U-500✔ Enables delivery of a highly concentrated, low volume injection, offering more effective mealtime glucose control to meet growing unmet need in patients requiring high daily doses of insulin✔ Creates potential to be the first, and only, ultra-concentrated (500 U/mL) ultra-rapid insulin product enabling miniaturisation of next-generation insulin pumpsSarah Howell, our CEO, and Thomas Pieber, Principal Investigator for the trial, will hold a CEO and KOL webinar tomorrow at 2.30pm BST.Register to join the live webcast here: https://lnkd.in/eC8rXwVyRead the full announcement here: https://arecor.com/news/#Arecor #insulin #diabetes #biotech #insulinpumps

46

3 Comments

We are honoured to have received the ‘Highly Commended’ award for Biotech Company of the Year at the Cambridge Independent Science and Technology Awards, which took place last night. Thank you to our CSO Jan Jezek Jazek and Rafic Sukar, AMRSC, one of Arecor’s formulation scientists, for attending and receiving the award on behalf of Arecor. Congratulations to Crescendo Biologics Limited, the winner of Biotech Company of the Year and a big thank you to the organisers for putting together a great event.#Arecor #Awards #Diabetes #biotech

25

Our CEO, Sarah Howell, sat down with Proactive to discuss the highlights from Arecor’s Full Year 2023 results, including the significant progress made by our partners under licence as well as the continued development progress across our in-house and proprietary product portfolio, touching on the upcoming AT278 clinical trial which is on track for key data readout in H1 2024. #Arecor #financialresults #diabetes #biotech #drugDevelopment

14

Today we announced our financial results for the year ended 31 December 2023 highlighting another strong year for Arecor with delivery across all areas of the business. Key updates include:✔ Continued momentum in diabetes portfolio with AT278 clinical trial on track for key data readout in H1 2024✔ First commercial launch of Arestat™ enabled product licensed to partner, AT220, triggering a milestone payment and recurring royalties✔ Further expansion of partnership portfolio and licensing of products incorporating ourArestat™ technology✔ Tetris Pharma product sales increasing to £2.9 million (2022: £1.1 million)✔ Total Group revenue of £4.6 million (2022: £2.4 million), 90% year-on-year growthWe will be hosting a webcast for analysts and investors later this morning at 11am BST, to join virtually register here: https://lnkd.in/e8JVA2fg To view our 2023 results statement, please visit: https://lnkd.in/efxaesHT#financialresults #Arecor #drugDevelopment #biotech #diabetes

33

Heading to Bio€quity Europe 2024?Our Chief Executive Officer, Sarah Howell, will be presenting next Monday 13 May at 11.30am CEST in San Sebastian, Spain at the Kursaal Elkargunea Center.If you are attending and would like to arrange a meeting, please get in contact. #BioEquityEurope #Arecor #drugDevelopment #biotech

18

Today we announced an important #collaboration with Medtronic, leveraging our diabetes expertise to develop an enhanced insulin for intraperitoneal therapy via an implantable pump for people with #Type1 diabetes.Intraperitoneal therapy is a key treatment option for people living with Type 1 diabetes who cannot tolerate conventional insulin therapies. This is a vulnerable patient group, and we are proud to be combining our expertise in developing differentiated insulins with Medtronic who are pioneers in implantable insulin pump systems.Find out more about our collaboration here: https://arecor.com/news/ #Arecor #Medtronic #diabetes #biotech

35

#ICYMI: Katerina-Asteria Rousou, one of our talented R&D scientists, recently spoke to us about what motivated her to become a #scientist, delving into her role at Arecor and touching on who her science heroes are.#Arecor #employee #Biotech

16

We recently sat down with Katerina-Asteria Rousou to discuss her work at Arecor Therapeutics as a scientist in the R&D team and how she came to be part of the team at Cambridge (rather than an archaeological dig in Egypt…).#Arecor #employee #Biotech #research

41

5 Comments